Jan 10, 2023 / 11:45PM GMT
Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
Good afternoon, everyone. My name is Daniel Wolle. I'm one of the analysts at JPMorgan covering biotech. It's my pleasure to introduce Mark Enyedy from ImmunoGen. Following the presentations, you have the opportunity to ask questions. You can do that either through the portal or you can ask. There will be a mic going around, so you can pick up the mic and ask questions. Without further ado, Mark?
Mark Joseph Enyedy - ImmunoGen, Inc. - President, CEO & Director
Good afternoon. Our thanks to Daniel and the rest of the team at JPMorgan for the opportunity to speak with you today.
Our presentation contains forward-looking statements. Please refer to our SEC filings for the risks and uncertainties that could cause our actual result to vary from those statements.
So for those of you who are new to ImmunoGen or revisiting our story, we are generating the next generation of ADCs to improve outcomes for cancer patients. With the recent approval and launch of ELAHERE, we've
ImmunoGen Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers